TORONTO, June 27, 2023 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has filed a Pre-Submission Facility Correspondence in advance of its Abbreviated New Drug Application (“ANDA”) for KETARX (racemic ketamine) to the Food and Drug Administration (“FDA”) to…


Previous articlePT419 – Ketamine-Assisted Therapy for Severe Alcohol Use Disorder
Next articleAn Abridged History of Psychedelic Use and Criminalisation